Skip to content

Released Aug 8, 2023, after the close

10-Q filed Aug 8, 2023, 39 days after period end · 0000950170-23-039803

Q2 2023 · 10-Q
Revenue$933.00K−95.0% vs Q2 2022−98.4% vs Q1 2023
Net Income-$52.76MN/M vs Q2 2022N/M vs Q1 2023
EPS Diluted-$0.54N/M vs Q2 2022N/M vs Q1 2023
Operating Income-$62,565,000N/M
Operating Cash Flowderived-$28,493,000N/M
Free Cash Flowderived-$30,692,000N/M
Margins · derived
Operating margin-6705.8%−6257.7 pt vs Q2 2022
Net margin-5654.3%−5244.0 pt vs Q2 2022

What the release said

The release

Same quarter

MetricQ2 2023Q2 2022Q2 2021Q2 2020
Revenue$933.00K$18.55M$13.41M$5.47M
Net Income-$52.76M-$76.11M-$55.13M-$28.07M
EPS Diluted-$0.54-$0.79-$0.58-$0.35

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR